Recurrent Platinum-resistant Epithelial Ovarian Cancer

Recurrent platinum-resistant epithelial ovarian cancer (PREOC) is one of the most common types of ovarian cancer, with approximately 90% of all ovarian cancers being of this type. As the name implies, PREOC is resistant to platinum-based chemotherapy, but can often respond to alternative treatments. PREOC is an aggressive cancer, with a median survival rate of around 48 months for those receiving standard treatment.

PREOC usually presents as a pelvic mass, often accompanied by ascites (fluid accumulation in the abdomen), gastrointestinal symptoms, and general signs of tumor growth. Diagnosis typically involves imaging studies (CT/MRI/ultrasound), blood tests, and biopsy. Progression of the cancer is monitored using various means including CA 125 levels.

For those with platinum-resistant PREOC, there are a number of treatment options that may be considered. These include:

Chemotherapy: Chemotherapy can be used to treat PREOC in some cases, although it may not be effective for all types of PREOC. Common chemotherapy agents used to treat PREOC include topotecan, paclitaxel, and gemcitabine.
Targeted therapy: Targeted therapies are used to target specific proteins or pathways active in PREOC, and can be used alone or in combination with traditional chemotherapy drugs. Common targeted therapies used to treat PREOC include bevacizumab, olaparib, and cetuximab.
Radiation therapy: Radiation therapy may also be used to treat PREOC in some cases, although patient selection is very important as the radiation may not be effective for all patients.
Surgery: Surgery may be used to remove visible tumors or to enhance the effectiveness of other treatments. Total hysterectomy, omentectomy, and lymph node dissection are common surgical procedures used to treat PREOC.
Clinical trials: In some cases, PREOC patients may be eligible to participate in clinical trials of new treatments which may be more effective than traditional treatments.

Recurrent platinum-resistant epithelial ovarian cancer is a very aggressive cancer, and the treatment options are limited. It is important to discuss treatment options with your doctor and seek out clinical trials if possible. With the right treatment, PREOC can be managed successfully.